REGENXBIO to Host Conference Call for Financial Insights
REGENXBIO Inc. (Nasdaq: RGNX) has exciting news to share! The company plans to hold a conference call focused on their financial results for the fourth quarter and the full year, recently closing on December 31, 2024. This event is slated for Thursday, March 13, at 4:30 p.m. ET, and all interested listeners are invited to tune in for essential updates.
How to Join the Conference Call
Those looking to participate can register for the webcast to hear directly from the company about their financial position and recent operational efforts. For analysts eager to engage in the Q&A session, a separate registration is available, ensuring they can pose inquiries relevant to the call's content. A recorded version of the webcast will be accessible approximately two hours post-call, allowing attendees to catch up on any missed portions of the discussion. It is recommended for participants to log in at least 15 minutes early to prepare for the start.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has emerged as a leader in biotechnology, focusing on the transformative potential of gene therapy. The company is dedicated to enhancing the lives of patients through innovative genetic treatments. Their commitment to the development of AAV Therapeutics distinguishes them in the field of gene therapy. These therapies have shown promise not only for rare genetic conditions but also for retinal diseases. Key advancements in their pipeline include RGX-202 aimed at treating Duchenne Muscular Dystrophy, ABBV-RGX-314 for managing wet age-related macular degeneration and diabetic retinopathy—with collaboration from AbbVie—and RGX-121 intended for treating Mucopolysaccharidosis type II.
Community Impact of AAV Therapeutics
Thousands have benefited from treatments based on REGENXBIO’s AAV Therapeutic platform, which includes notable therapies like Novartis' Zolgensma, designed for children battling spinal muscular atrophy. These one-time treatments carry the capacity to redefine health care for millions, paving the way for cures rather than management of diseases. As REGENXBIO continues its pioneering initiatives, the broader community can expect further innovations that have the potential to change lives.
Investors and Media Contacts
For corporate communications, Dana Cormack is available to answer inquiries regarding the upcoming conference call and other company matters. If investors have questions, George E. MacDougall, representing investor relations, is also ready to assist with information relevant to stockholders and financial inquiries. REGENXBIO values transparency and encourages engagement from their community, whether through direct calls, inquiries, or future updates provided on their official website.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss REGENXBIO's financial results for the fourth quarter and share updates on operational highlights.
When is the conference call scheduled?
The conference call is set for March 13 at 4:30 p.m. ET.
Who can participate in the Q&A session?
Analysts wishing to engage in the Q&A session must register separately to be part of that discussion.
How can I access the replay of the conference call?
A replay of the conference call will be available on REGENXBIO's investor website approximately two hours after the event concludes.
What advancements is REGENXBIO working on?
REGENXBIO is advancing AAV Therapeutics for various conditions, including treatments for Duchenne muscular dystrophy and retinal diseases.
